MK
Therapeutic Areas
Santen Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DE-130 (Eicosapentaenoic Acid Ethyl Ester) | Dry Eye Disease | Phase 3 |
| DE-126 (SIP Receptor Modulator) | Dry Eye Disease | Phase 2 |
| DE-127 | Dry Eye Disease | Phase 1 |
| SE-1003 | Glaucoma / Ocular Hypertension | Phase 2 |
| DE-128A | Ocular Inflammation / Pain | Phase 1 |
| SJP-0135 (Anti-VEGF) | Retinal Diseases (e.g., nAMD, DME) | Preclinical |
| OMNI (Sustained Release Bimatoprost Implant) | Glaucoma | Approved |
| Verkazia® (ciclosporin) | Vernal Keratoconjunctivitis | Approved |
Leadership Team at Santen Pharmaceutical
ST
Shigeo Taniuchi
Representative Director, President and Chief Executive Officer
HM
Hiroshi Matsumura
Representative Director, Executive Vice President
NS
Naveed Shams
Senior Vice President, Head of Global R&D
TI
Takayoshi Inoue
Senior Vice President, Head of Japan Commercial
PJ
Peter J. Lang
Senior Vice President, Head of Europe Commercial
YK
Yoshiki Kagawa
Senior Vice President, Head of Asia Commercial
L(
Louis (Lou) Mattis
Chairman and CEO, Santen Inc. (U.S. subsidiary)
AM
Atsushi Minagawa
Senior Vice President, Head of Corporate Strategy & Finance
YK
Yoshikazu Kato
Senior Vice President, Head of Manufacturing & Supply Chain
YN
Yoshitsugu Nakamura
Senior Vice President, Head of Legal, Compliance & Quality Assurance